SLG
ZYME icon

Stanley-Laman Group’s Zymeworks ZYME Stock Holding History

Stanley-Laman Group’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-56,490
Closed -$887K – 301
2018
Q3 		$887K Buy
+56,490
New +$808K 0.22% 138
2018
Q2 		– Sell
-36,556
Closed -$439K – 277
2018
Q1 		$439K Buy
+36,556
New +$395K 0.1% 225

Other funds holding ZYME

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Stanley-Laman Group's ZYME Position: Q4 2018 in Review

Stanley-Laman Group sold out of Zymeworks (ZYME) in Q4 2018, closing a stake of 56,490 shares — an estimated $887K sold.

Stanley-Laman Group first reported a position in ZYME in Q1 2018 and held it in 2 quarters. The position peaked at $887K in Q3 2018. 43 funds tracked by Wall St. Rank hold ZYME as of Q4 2018.

  • Stanley-Laman Group reported no remaining Zymeworks position as of Q4 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 56,490 Zymeworks shares in Q4 2018, an estimated $887K.
  • Stanley-Laman Group first reported a position in Zymeworks in Q1 2018 and held it in 2 quarters.
  • Stanley-Laman Group's Zymeworks position peaked at $887K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Zymeworks as of Q4 2018.

Based on Stanley-Laman Group's 13F filing for Q4 2018, filed 7 Feb 2019.